Matches in SemOpenAlex for { <https://semopenalex.org/work/W2725270245> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2725270245 endingPage "421" @default.
- W2725270245 startingPage "416" @default.
- W2725270245 abstract "The aim of this review is to assess the effect of genetic factors on the pharmacokinetic parameters of new oral anticoagulants. The review presents data from studies investigating the effect of gene polymorphisms that encode biotransformation enzymes and transporter proteins of new oral anticoagulants on the pharmacokinetics of these drugs. RE-LY study showed a 15% decrease in trough dabigatran concentration and 27% lower risk of bleeding in carriers of CES1 gene rs2244613 polymorphism, there was also a tendency to reduce the risk of major bleeding. Further study of CES1 gene rs8192935 polymorphism showed a 3% decrease in trough dabigatran concentration in heterozygotes and 11% in homozygotes. There was found a 2% and 3% decrease in trough concentrations in hetero- and homozygotes for the minor allele of CES1 gene rs2244613 polymorphism, respectively. There was no significant effect of ABCB1 gene rs2032582 and rs1045642 polymorphisms on dabigatran pharmacokinetics. It is known the case of gastrointestinal bleeding in the carrier of allelic variants of ABCB1 gene rs2032582 and rs1045642 polymorphisms. However, there was no significant effect of genotype on rivaroxaban pharmacokinetics in the study involving the carriers of ABCB1 gene rs2032582 and rs1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak concentration. But groups of patients with acute cardioembolic stroke showed no statistically significant difference of apixaban peak concentration depending on ABCB1 gene rs1045642 polymorphism genotype. ABCB1 gene rs1045642 and SLCO1B1 gene rs4149056 polymorphisms have no effect on edoxaban pharmacokinetics. Elevation of edoxaban metabolite concentration in carriers of SLCO1B1 gene allelic variants was not clinically significant because the proportion of metabolite is about 10% of the concentration of the main substance. It is necessary to provide large population studies with control of treatment efficacy and safety to prove clinical significance of genotyping for new oral anticoagulants use." @default.
- W2725270245 created "2017-07-14" @default.
- W2725270245 creator A5002647227 @default.
- W2725270245 creator A5014465688 @default.
- W2725270245 creator A5064324725 @default.
- W2725270245 date "2017-01-01" @default.
- W2725270245 modified "2023-09-23" @default.
- W2725270245 title "PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION" @default.
- W2725270245 doi "https://doi.org/10.20996/1819-6446-2017-13-3-416-421" @default.
- W2725270245 hasPublicationYear "2017" @default.
- W2725270245 type Work @default.
- W2725270245 sameAs 2725270245 @default.
- W2725270245 citedByCount "4" @default.
- W2725270245 countsByYear W27252702452019 @default.
- W2725270245 countsByYear W27252702452022 @default.
- W2725270245 countsByYear W27252702452023 @default.
- W2725270245 crossrefType "journal-article" @default.
- W2725270245 hasAuthorship W2725270245A5002647227 @default.
- W2725270245 hasAuthorship W2725270245A5014465688 @default.
- W2725270245 hasAuthorship W2725270245A5064324725 @default.
- W2725270245 hasBestOaLocation W27252702451 @default.
- W2725270245 hasConcept C104317684 @default.
- W2725270245 hasConcept C126322002 @default.
- W2725270245 hasConcept C135763542 @default.
- W2725270245 hasConcept C177713679 @default.
- W2725270245 hasConcept C185592680 @default.
- W2725270245 hasConcept C2776301958 @default.
- W2725270245 hasConcept C2778661090 @default.
- W2725270245 hasConcept C2778810321 @default.
- W2725270245 hasConcept C2779161974 @default.
- W2725270245 hasConcept C55493867 @default.
- W2725270245 hasConcept C55775858 @default.
- W2725270245 hasConcept C71924100 @default.
- W2725270245 hasConceptScore W2725270245C104317684 @default.
- W2725270245 hasConceptScore W2725270245C126322002 @default.
- W2725270245 hasConceptScore W2725270245C135763542 @default.
- W2725270245 hasConceptScore W2725270245C177713679 @default.
- W2725270245 hasConceptScore W2725270245C185592680 @default.
- W2725270245 hasConceptScore W2725270245C2776301958 @default.
- W2725270245 hasConceptScore W2725270245C2778661090 @default.
- W2725270245 hasConceptScore W2725270245C2778810321 @default.
- W2725270245 hasConceptScore W2725270245C2779161974 @default.
- W2725270245 hasConceptScore W2725270245C55493867 @default.
- W2725270245 hasConceptScore W2725270245C55775858 @default.
- W2725270245 hasConceptScore W2725270245C71924100 @default.
- W2725270245 hasIssue "3" @default.
- W2725270245 hasLocation W27252702451 @default.
- W2725270245 hasLocation W27252702452 @default.
- W2725270245 hasOpenAccess W2725270245 @default.
- W2725270245 hasPrimaryLocation W27252702451 @default.
- W2725270245 hasRelatedWork W1568966348 @default.
- W2725270245 hasRelatedWork W1984954114 @default.
- W2725270245 hasRelatedWork W2032118176 @default.
- W2725270245 hasRelatedWork W2399439482 @default.
- W2725270245 hasRelatedWork W2515183968 @default.
- W2725270245 hasRelatedWork W2519630846 @default.
- W2725270245 hasRelatedWork W2554174230 @default.
- W2725270245 hasRelatedWork W2582505536 @default.
- W2725270245 hasRelatedWork W2609267468 @default.
- W2725270245 hasRelatedWork W2779906290 @default.
- W2725270245 hasVolume "13" @default.
- W2725270245 isParatext "false" @default.
- W2725270245 isRetracted "false" @default.
- W2725270245 magId "2725270245" @default.
- W2725270245 workType "article" @default.